Pharmacogenetics of escitalopram and mental adaptation to cancer in palliative care: Report of 18 cases

Tumori

Volumn 97, Issue 3, 2011, Pages 358-361

  Schillani, Giulia ^a   Capozzo, Maria Anna ^a   Era, Daniel ^a   De Vanna, Maurizio ^a   Grassi, Luigi ^b   Conte, Maria Anna ^c   Giraldi, Tullio ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

^c Civile Hospital   (Italy)

Author keywords

Antidepressant drugs; Mental adaptation to cancer; Palliative care; Pharmacogenetics

Indexed keywords

ANALGESIC AGENT; BENZODIAZEPINE DERIVATIVE; ESCITALOPRAM; NARCOTIC ANALGESIC AGENT; NEUROLEPTIC AGENT; SEROTONIN TRANSPORTER;

5 HYDROXYTRYPTAMINE TRANSPORTER GENE; ADAPTIVE BEHAVIOR; ADVANCED CANCER; ANXIETY DISORDER; ARTICLE; CANCER PALLIATIVE THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HELPLESSNESS; HOPELESSNESS; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; MALE; MINI MENTAL ADJUSTMENT TO CANCER SCALE; PAIN; PHARMACOGENETICS; PSYCHOLOGICAL RATING SCALE; PSYCHOMETRY; SCORING SYSTEM; TREATMENT DURATION;

ADAPTATION, PSYCHOLOGICAL; ADULT; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANXIETY; CITALOPRAM; FEMALE; HUMANS; ITALY; MALE; MIDDLE AGED; NEOPLASMS; PALLIATIVE CARE; POLYMORPHISM, GENETIC; SEROTONIN UPTAKE INHIBITORS;

EID: 79960869990     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1700/912.10034     Document Type: Article

References (24)

1. Massie MJ: Prevalence of depression in patients with cancer. Natl Cancer Inst Monogr, 32: 57-71, 2004.
2. Reich M: Depression and cancer: recent data on clinical issues, research challenges and treatment approaches. Curr Opin Oncol, 20: 353-359, 2008.
3. Grassi L, Rosti G, Albieri G, Marangolo M: Depression and abnormal illness behaviour in cancer patients. Gen Hosp Psychiatry, 11: 404-411, 1989. (Pubitemid 19277812)
4. Grassi L, Biancosino B, Marmai L, Righi R: Effect of reboxetine on major depressive disorder in breast cancer patients: an open-label study. J Clin Psychiatry, 65: 515-520, 2004.
5. Zigmond AS, Snaith RP: The hospital anxiety and depression scale. Acta Psychiatr Scand, 67: 361-370, 1983. (Pubitemid 13098606)
6. Watson M, Law M, Dos Santos M, Greer S, Baruch J, Bliss J: The Mini-Mac: further development of the Mental Adjustment to Cancer scale. J Psychosoc Oncol, 12: 33-46, 1994. (Pubitemid 24362754)
7. Berney A, Stiefel F, Mazzocato C, Buclin T: Psychopharmacology in supportive care of cancer: a review for the clinicians. III. Antidepressant. Support Care Cancer, 8: 278-286, 2000. (Pubitemid 30430050)
8. Miller KE, Adams SM, Miller MM: Antidepressant medication use in palliative care. Am J Hosp Palliat Care, 23: 127- 133, 2006.
9. Miovic M, Block S: Psychiatric disorders in advanced cancer. Cancer, 110: 1665-1676, 2007. (Pubitemid 47557291)
10. Fisch MJ, Loehrer PJ, Kristeller J, Passik S, Jung SH, Shen J, Arquette MA, Brames MJ, Einhorn LH; Hoosier Oncology Group: Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group. J Clin Oncol, 21: 1937-1943, 2003. (Pubitemid 46606381)
11. Stockler MR, O'Connell R, Nowak AK, Goldstein D, Turner J, Wilcken NR, Wyld D, Abdi EA, Glasgow A, Beale PJ, Jefford M, Dhillon H, Heritier S, Carter C, Hickie IB, Simes RJ: Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial. Lancet Oncol, 8: 603-612, 2007. (Pubitemid 46995622)
12. Schillani G, Capozzo MA, Aguglia E, De Vanna M, Grassi L, Conte MA, Giraldi T: 5-HTTLPR polymorphism of serotonin transporter and effects of sertraline in terminally ill cancer patients: report of eleven cases. Tumori, 94: 563-567, 2008.
13. Capozzo MA, Schillani G, Aguglia E, De Vanna M, Grassi L, Conte MA, Giraldi T: Serotonin transporter 5-HTTLPR polymorphismand response to citalopramin terminally ill cancer patients: report of twenty-one cases. Tumori, 95: 479-483, 2009.
14. Kim, SY, Kim, JM, Kim, SW, MD, PhD, Shin, S, Yoon, JS: Management of depression in terminally ill cancer patients. Korean J Psychopharmacol, 21: 51-61, 2010.
15. Yu YW, Tsai SJ, Chen TJ, Lin CH, Hong CJ: Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Mol Psychiatry, 10: 1115-1119, 2002. (Pubitemid 36044271)
16. Perlis RH, Mischoulon D, Smoller JW, Wan YY, Lamon-Fava S, Lin K, Rosenbaum JF, Fava M: Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. Biol Psychiatr, 54: 879-883, 2003. (Pubitemid 37311349)
17. Durham LK, Webb SM, Milos PM, Clary CM, Seymour AB: The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder. Psychopharmacology (Berl), 17: 525-529, 2004. (Pubitemid 39119341)
18. Serretti A, Mandelli L, Lorenzi C, Pirovano A, Oliati P, Colombo C, Smeraldi E: Serotonin transporter gene influences the time course of improvement of "core" depressive and somatic anxiety symptoms during treatment with SSRIs for recurrent mood disorders. Psychiatry Res, 149: 185-193, 2007. (Pubitemid 46108104)
19. Luddington NS, Mandadapu A, Husk M, El-Mallakh RS: Clinical implications of genetic variation in the serotonin transporter promoter region: a review. PrimCare Companion J Clin Psychiatry, 11: 93-102, 2009.
20. Gelernter J, Kranzler H, Cubells JF: Serotonin transporter protein (SLC6A4) allele and haplotype frequencies and linkage disequilibria in African- and European-American and Japanese populations and in alcohol-dependent subjects. Hum Genet, 101: 243-246, 1997. (Pubitemid 28014742)
21. Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, Benjamin J, Müller CR, Hamer DH, Murphy DL: Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science, 274: 1527-1531, 1996. (Pubitemid 26403928)
22. Sim SC, Nordin L, Andersson TM, Virding S, Olsson M, Pedersen NL, Ingelman-Sundberg M: Association between CYP2C19 polymorphism and depressive symptoms. Am J Med Genet B Neuropsychiatr Genet, 153B: 1160-1166, 2010.
23. Tsai MH, Lin KM, Hsiao MC, Shen WW, Lu ML, Tang HS, Fang CK, Wu CS, Lu SC, Liu SC, Chen CY, Liu YL: Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response. Pharmacogenomics, 11: 537-546, 2010.
24. Uhr M, Tontsch A, Namendorf C, Ripke S, Lucae S, Ising M, Dose T, Ebinger M, Rosenhagen M, Kohli M, Kloiber S, Salyakina D, Bettecken T, Specht M, Pütz B, Binder EB, Müller-Myhsok B, Holsboer F: Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron, 57: 203-209, 2008.